<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00749892</url>
  </required_header>
  <id_info>
    <org_study_id>2007-0704</org_study_id>
    <secondary_id>NCI-2018-01833</secondary_id>
    <secondary_id>2007-0704</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT00749892</nct_id>
  </id_info>
  <brief_title>Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer</brief_title>
  <official_title>A Phase II Exploratory Study of Pre-Operative Treatment With Erlotinib (Tarceva) in Muscle Invasive or Recurrent Transitional Cell Carcinoma Requiring Cystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well erlotinib hydrochloride works in Treating participants&#xD;
      with muscle invasive urothelial cancer or urothelial cancer that has come back. Drugs used in&#xD;
      chemotherapy, such as erlotinib hydrochloride, work in different ways to stop the growth of&#xD;
      tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them&#xD;
      from spreading.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the response rate (ie: pT0 rate) of patients with urothelial cancer treated&#xD;
      with erlotinib prior to cystectomy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the 4-year disease-free survival of patients with urothelial cancer treated&#xD;
      with erlotinib prior to cystectomy.&#xD;
&#xD;
      II. To measure epithelial-mesenchymal transition (EMT) markers (E-cadherin, HER4, PDGFR-beta,&#xD;
      vimentin, fibronectin) in pre- and post-treatment biopsies and correlate expression patterns&#xD;
      with the biological responses measured below.&#xD;
&#xD;
      III. To quantify target inhibition, antiproliferation (KI-67), and apoptosis (terminal&#xD;
      deoxynucleotidyl transferase dUTP nick end labeling [TUNEL]) in biopsies obtained from&#xD;
      patients before, during, and after therapy.&#xD;
&#xD;
      IV. Interrogate membrane (phosphorylated EGFR) and downstream receptor signaling pathways&#xD;
      (ERKs, AKT/mTOR, GSK-3beta) to provide further insight into whether or not a given tumor&#xD;
      displays a biological response.&#xD;
&#xD;
      V. To correlate the changes in Ki-67 expression with changes in angiogenesis and angiogenesis&#xD;
      related gene expression utilizing fluorescent tissue staining techniques that we have&#xD;
      developed in the laboratory (such as two-color TUNEL, phosphor-receptor, and microvessel&#xD;
      density.) VI. To profile messenger ribonucleic acid (mRNA) expression in pre- and&#xD;
      post-treatment biopsies using Affymetrix arrays and correlate the changes observed with EMT,&#xD;
      growth arrest, and apoptosis.&#xD;
&#xD;
      VII. To quantify EGFR copy number and correlate with changes observed with EMT, growth&#xD;
      arrest, and apoptosis.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Participants receive erlotinib hydrochloride orally (PO) once daily (QD) for 3-5 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity. Within 24 hours of the last dose,&#xD;
      participants undergo cystectomy.&#xD;
&#xD;
      After completion of study treatment, participants are followed up every 6 months for 1 year,&#xD;
      then annually for 4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 10, 2008</start_date>
  <completion_date type="Actual">November 26, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Determined at the time of surgery or cystectomy</time_frame>
    <description>The response rate is the number of patients with urothelial cancer treated with erlotinib prior to cystectomy. The response is defined as the absence of residual cancer in the surgical removed tissue (i.e., pT0). A responder is defined as a participant with the pathological stage of pT0 meaning that there is no evidence of disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated 4-Year Disease-Free Survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Recurrent Bladder Urothelial Carcinoma</condition>
  <condition>Recurrent Renal Pelvis Urothelial Carcinoma</condition>
  <condition>Recurrent Ureter Urothelial Carcinoma</condition>
  <condition>Recurrent Urethral Urothelial Carcinoma</condition>
  <condition>Stage 0a Bladder Cancer AJCC v8</condition>
  <condition>Stage 0a Renal Pelvis Cancer AJCC v8</condition>
  <condition>Stage 0a Ureter Cancer AJCC v8</condition>
  <condition>Stage 0a Urethral Cancer AJCC v8</condition>
  <condition>Stage 0is Bladder Cancer AJCC v8</condition>
  <condition>Stage 0is Renal Pelvis Cancer AJCC v8</condition>
  <condition>Stage 0is Ureter Cancer AJCC v8</condition>
  <condition>Stage 0is Urethral Cancer AJCC v8</condition>
  <condition>Stage II Bladder Cancer AJCC v8</condition>
  <condition>Stage II Renal Pelvis Cancer AJCC v8</condition>
  <condition>Stage II Ureter Cancer AJCC v8</condition>
  <condition>Stage II Urethral Cancer AJCC v8</condition>
  <condition>Stage III Renal Pelvis Cancer AJCC v8</condition>
  <condition>Stage III Ureter Cancer AJCC v8</condition>
  <condition>Stage III Urethral Cancer AJCC v8</condition>
  <condition>Stage IIIA Bladder Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Treatment (erlotinib hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive erlotinib hydrochloride PO QD for 3-5 weeks in the absence of disease progression or unacceptable toxicity. Within 24 hours of the last dose, participants undergo cystectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (erlotinib hydrochloride)</arm_group_label>
    <other_name>Cp-358,774</other_name>
    <other_name>OSI-774</other_name>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologic proof of urothelial cancer. This includes bladder&#xD;
             cancer, in addition to other tumors of the urothelial lining including renal pelvis,&#xD;
             ureteral, and urethral cancer. This group may include any patient requiring&#xD;
             cystectomy, including patients with recurrent or extensive superficial disease&#xD;
             (cTa-T1N0M0), CIS (carcinoma in situ), or muscle invasive disease (cT2-3aN0M0), whose&#xD;
             tumor could not be completely removed at transurethral resection&#xD;
&#xD;
          -  Patients with the following high-risk features: Micropapillary features (more than&#xD;
             focal on pathology); Small cell carcinoma; 3-dimensional (D) mass on exam under&#xD;
             anesthesia (EUA); Lymphovascular invasion; Hydronephrosis (unless in the opinion of&#xD;
             the treating physician, this is not due to tumor); High grade (grade 3) tumors of the&#xD;
             ureter, renal pelvis, or urethra, or tumors in these areas with radiographic&#xD;
             abnormality large enough to recognize as an abnormal mass by computed tomography (CT)&#xD;
             or magnetic resonance imaging (MRI) imaging; Direct invasion of the prostatic stroma&#xD;
             or the vaginal wall (ie: cT4a disease) should be offered neoadjuvant cytoreductive&#xD;
             chemotherapy (ie: cisplatin-based). Patients refusing or who are not considered&#xD;
             candidates for cytoreductive chemotherapy may be considered eligible. Dr.&#xD;
             Siefker-Radtke will be the final arbiter in determining eligibility for the trial&#xD;
&#xD;
          -  Please note that the presence of variant histologic subtypes is acceptable, except in&#xD;
             the case for small cell variant which is traditionally treated with cytoreductive&#xD;
             chemotherapy. Patients with small cell who refuse recommended cytoreductive&#xD;
             chemotherapy may still be considered eligible&#xD;
&#xD;
          -  Patients must have an evaluation in the department of urology, and be deemed an&#xD;
             acceptable surgical candidate&#xD;
&#xD;
          -  Patients must NOT have clinical evidence of metastatic disease by either CT or MRI of&#xD;
             the abdomen and pelvis, and chest x-ray. In the absence of a bone scan, patients&#xD;
             should be free of bone pain and have an alkaline phosphatase &lt; 1.5 x upper limit of&#xD;
             normal (ULN) of the upper limit of normal, or a normal bone fraction of alkaline&#xD;
             phosphatase. If these features are present, patients should have a bone scan and this&#xD;
             should be interpreted as showing no evidence of metastatic disease in order to be&#xD;
             eligible&#xD;
&#xD;
          -  Patients, 18 years and older, must either be not of child bearing potential or have a&#xD;
             negative pregnancy test within 2 weeks of treatment. Patients are considered not of&#xD;
             child bearing potential if they are surgically sterile (they have undergone a&#xD;
             hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are&#xD;
             postmenopausal&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,000/ul&#xD;
&#xD;
          -  Platelets &gt;= 75,000/microliters&#xD;
&#xD;
          -  Creatinine =&lt; 2.0 x institutional upper limit of normal (ULN), or a creatinine&#xD;
             clearance of &gt; 30 ml/min as calculated by Cockroft-Gault or by 24-hour urine&#xD;
             collection&#xD;
&#xD;
          -  Bilirubin =&lt; 2.5 x ULN&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) =&lt; 5.0 x ULN&#xD;
&#xD;
          -  Zubrod performance status (PS) =&lt; 2&#xD;
&#xD;
          -  Patients with second malignancies are eligible provided that the expected outcome from&#xD;
             the second cancer is such that this will not interfere in the delivery of this&#xD;
             therapy, or in doing cystectomy, and provided that the expectation of survival from&#xD;
             any prior malignancy is reliably &gt; 4 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute hepatitis or known human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Active or uncontrolled infection&#xD;
&#xD;
          -  Significant history of uncontrolled cardiac disease; i.e., uncontrolled hypertension,&#xD;
             unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled&#xD;
             congestive heart failure, and cardiomyopathy with decreased ejection fraction =&lt; 40%&#xD;
&#xD;
          -  Prior therapy specifically and directly targeting the EGFR pathway&#xD;
&#xD;
          -  Patients with interstitial lung disease&#xD;
&#xD;
          -  Any concurrent chemotherapy not indicated in the study protocol or any other&#xD;
             investigational agent(s)&#xD;
&#xD;
          -  Patients with metastatic or surgically unresectable disease are not eligible for this&#xD;
             study. In addition, patients who do not agree to surgery are not eligible for this&#xD;
             trial&#xD;
&#xD;
          -  Patients who have received prior systemic chemotherapy or radiation therapy for&#xD;
             urothelial cancer are not eligible. Any prior intravesical chemotherapy is allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arlene Siefker-Radtke</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 5, 2008</study_first_submitted>
  <study_first_submitted_qc>September 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <results_first_submitted>June 5, 2020</results_first_submitted>
  <results_first_submitted_qc>August 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 10, 2020</results_first_posted>
  <last_update_submitted>August 21, 2020</last_update_submitted>
  <last_update_submitted_qc>August 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Urethral Neoplasms</mesh_term>
    <mesh_term>Ureteral Neoplasms</mesh_term>
    <mesh_term>Pelvic Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 11, 2009</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT00749892/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began 6/9/2008 and concluded on 12/19/2011 in the medical clinic. Diagnosis of invasive transitional cell carcinoma in the bladder, upper tract or urethra tumors were required for participants who were candidates for cystectomy to be considered. Participants with high-risk features were generally excluded.</recruitment_details>
      <pre_assignment_details>Erlotinib treatment milestone: Three participants decided to not start the study medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pre-surgical Erlotinib Treatment</title>
          <description>Erlotinib 150 mg by mouth daily for 3 weeks followed by cystectomy within 24 hours of the last dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants were stagged clinically before treatment began. The T discribes the tumor size; the larger the number is the more advanced the disease. The N indicates the lymphpnode involvemnt; zero indicates that no lymph nodes were believed to be cancerous.</population>
      <group_list>
        <group group_id="B1">
          <title>Pre-surgical Erlotinib Treatment</title>
          <description>Erlotinib 150 mg by mouth daily for 3 weeks followed by cystectomy within 24 hours of the last dose.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="53" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Staging</title>
          <description>Participants were staged clinically before treatment began. The T describes the tumor size; the larger the number is the more advanced the disease. The N indicates the lymphnode involvement; zero indicates that no lymph nodes were believed to be cancerous.</description>
          <population>Three particpants withdrew from study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>cTaN0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cT1N0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cT2N0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cT3aN0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cT3bN0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cT4aN0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>The response rate is the number of patients with urothelial cancer treated with erlotinib prior to cystectomy. The response is defined as the absence of residual cancer in the surgical removed tissue (i.e., pT0). A responder is defined as a participant with the pathological stage of pT0 meaning that there is no evidence of disease.</description>
        <time_frame>Determined at the time of surgery or cystectomy</time_frame>
        <population>two participants did not take any eroltinib and three participants stopped erlotinib early due to intolerable side effects.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-surgical Erlotinib Treatment</title>
            <description>Erlotinib 150 mg by mouth daily for 3 weeks followed by cystectomy within 24 hours of the last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>The response rate is the number of patients with urothelial cancer treated with erlotinib prior to cystectomy. The response is defined as the absence of residual cancer in the surgical removed tissue (i.e., pT0). A responder is defined as a participant with the pathological stage of pT0 meaning that there is no evidence of disease.</description>
          <population>two participants did not take any eroltinib and three participants stopped erlotinib early due to intolerable side effects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Non Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated 4-Year Disease-Free Survival</title>
        <time_frame>4 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Evaluated for 2 months once drug therapy started.</time_frame>
      <desc>Toxicities were measured at weekly visit while on therapy using the NCI CTCAE v3.0.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pre-surgical Erlotinib Treatment</title>
          <description>Erlotinib 150 mg by mouth daily for 3 weeks followed by cystectomy within 24 hours of the last dose.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTCAE V3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Neutrophils/Grabulocytes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Decreased Leukocytes (Total WBD)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection-wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI CTCAE V3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Decreased Neutrophils/Grabulocytes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Arlene O. Siefker-Radtke,Professor, Genitourinary Medical Oncology</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>(713) 792-2830</phone>
      <email>asiefker@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

